Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Agenus Inc AGEN

Healthcare Biotechnology

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its... see more

Add To Watchlist

Recent & Breaking News (NDAQ:AGEN)

Agenus Inc. to Host Earnings Call

Accesswire November 7, 2017

New Research: Key Drivers of Growth for Coty, Bristol-Myers Squibb, Carnival, Agenus, Steel Dynamics, and Impax Labs - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire November 7, 2017

Agenus to Report Third Quarter 2017 Financial Results on November 7, 2017 and Host Conference Call and Webcast

PR Newswire October 26, 2017

Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles

PR Newswire October 25, 2017

40 Biggest Movers From Yesterday

Benzinga.com October 25, 2017

32 Stocks Moving In Monday's Mid-Day Session

Benzinga.com October 23, 2017

Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus

PR Newswire October 23, 2017

The Week Ahead: Earnings Season Starts In Earnest

Benzinga.com October 23, 2017

25 Stocks Moving In Monday's Pre-Market Session

Benzinga.com October 23, 2017

Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics

PR Newswire October 23, 2017

FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant

PR Newswire October 20, 2017

Biotech Stock Performance Review -- Agenus, Akebia Therapeutics, Acorda Therapeutics, and Advaxis

PR Newswire October 20, 2017

GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization from Health Canada

PR Newswire October 13, 2017

Biotech Investors, Here's Your PDUFA Primer For October

Benzinga.com September 28, 2017

Agenus to Present at Two Healthcare Investor Conferences In September

PR Newswire September 19, 2017

GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee recommendation for approval

PR Newswire September 13, 2017

FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over

PR Newswire September 13, 2017

Biotech Stocks on Investors' Radar -- PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences

PR Newswire September 12, 2017

How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics

PR Newswire August 4, 2017

Investor Network: Agenus Inc. to Host Earnings Call

Accesswire August 3, 2017